Clinuvel Pharmaceuticals LimitedASX: CUV

CLINUVEL files NEURACTHEL Instant dossier

· Issued by Clinuvel Pharmaceuticals Limited via ASX

Filed with ASX · · 3 pages · English

Summary by 6ix AI

Clinuvel Pharmaceuticals Limited has filed a dossier for its product NEURACTHEL® Instant with European regulatory agencies as part of the decentralized procedure in Europe. This product is a branded generic formulation of tetracosactide, a synthetic analogue of natural ACTH, aimed at addressing market gaps in Europe. The filing is significant as it marks Clinuvel's second pharmaceutical product submission, with potential commercialization in key EU member states if approved.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/clinuvel-files-neuracthel-instant-dossier-1

Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call

Release

A S X A N N O U N C E M E N T ASX: CUV | Nasdaq: CUVL | Börse Frankfurt: UR9 CLINUVEL files NEURACTHEL® Instant dossier Submission of ACTH product to first European regulatory agencies Executive Summary • CLINUVEL files NEURACTHEL® Instant through decentralised procedure in Europe • Branded...

Clinuvel Pharmaceuticals Limited on 6ix

Earlier from Clinuvel Pharmaceuticals

All Clinuvel Pharmaceuticals news releases